{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:59:29Z","timestamp":1792465169543,"version":"4.5.0"},"reference-count":295,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejps.2021.106094","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:33:18Z","timestamp":1639017198000},"page":"106094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines"],"prefix":"10.1016","volume":"169","author":[{"given":"Issa","family":"Sadeghian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sadeghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Raee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manica","family":"Negahdaripour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.106094_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.197986","article-title":"An in silico integrative protocol for identifying key genes and pathways useful to understand emerging virus disease pathogenesis","volume":"284","author":"de Souza","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.ejps.2021.106094_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101031","article-title":"Nanotechnology for virus treatment","volume":"36","author":"Zhou","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.ejps.2021.106094_bib0004","doi-asserted-by":"crossref","first-page":"170402","DOI":"10.1016\/j.peptides.2020.170402","article-title":"Peptides to combat viral infectious diseases","volume":"134","author":"Al-Azzam","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.ejps.2021.106094_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107245","article-title":"Interferon-inducer antivirals: potential candidates to combat COVID-19","volume":"91","author":"Bagheri","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0006","first-page":"81","article-title":"The battle against COVID-19: where do we stand now?","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0007","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jpba.2017.06.071","article-title":"Current antiviral drugs and their analysis in biological materials\u2014part i: antivirals against respiratory and herpes viruses","volume":"147","author":"Nov\u00e1kov\u00e1","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2021.106094_bib0008","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0009","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/acsinfecdis.6b00104","article-title":"Integration of global analyzes of host molecular responses with clinical data to evaluate pathogenesis and advance therapies for emerging and re-emerging viral infections","volume":"2","author":"Falcinelli","year":"2016","journal-title":"ACS Infect. Dis."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0010","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.micinf.2005.06.032","article-title":"Reasons for the increase in emerging and re-emerging viral infectious diseases","volume":"8","author":"Hui","year":"2006","journal-title":"Microbes Infect."},{"issue":"6996","key":"10.1016\/j.ejps.2021.106094_bib0011","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature02759","article-title":"The challenge of emerging and re-emerging infectious diseases","volume":"430","author":"Morens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2021.106094_bib0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.addr.2020.11.007","article-title":"Peptide and peptide-based inhibitors of SARS-CoV-2 entry","volume":"167","author":"Sch\u00fctz","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0013","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.coviro.2011.10.020","article-title":"Drug resistance in HIV-1","volume":"1","author":"Kuritzkes","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejps.2021.106094_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.110924","article-title":"An overview of functional nanoparticles as novel emerging antiviral therapeutic agents","volume":"112","author":"Chen","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","article-title":"Current progress in antiviral strategies","volume":"35","author":"Lou","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","volume":"88","author":"Owji","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejps.2021.106094_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173553","article-title":"Antiviral activity of chlorpromazine, fluphenazine, perphenazine, prochlorperazine, and thioridazine towards RNA-viruses. A review","volume":"887","author":"Otr\u0119ba","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0018","doi-asserted-by":"crossref","first-page":"14051","DOI":"10.3390\/molecules200814051","article-title":"Nanostructures for the inhibition of viral infections","volume":"20","author":"Szunerits","year":"2015","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/molecules23020335","article-title":"Review of current cell-penetrating antibody developments for HIV-1 therapy","volume":"23","author":"Che Nordin","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2021.106094_bib0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","article-title":"Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds","volume":"9","author":"Nan","year":"2018","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000220597","article-title":"TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication","volume":"52","author":"Meng","year":"2009","journal-title":"Intervirology"},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0022","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/ph3030448","article-title":"Cell-penetrating peptides for antiviral drug development","volume":"3","author":"Delcroix","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0023","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.addr.2009.06.001","article-title":"Recent advances in the use of cell-penetrating peptides for medical and biological applications","volume":"61","author":"Fonseca","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.106094_bib0024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.taap.2018.03.023","article-title":"TAT-mediated intracellular delivery of carboxypeptidase G2 protects against methotrexate-induced cell death in HepG2 cells","volume":"346","author":"Sadeghian","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"13","key":"10.1016\/j.ejps.2021.106094_bib0025","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.3390\/ijms21134696","article-title":"Conjugates of ciprofloxacin and levofloxacin with cell-penetrating peptide exhibit antifungal activity and mammalian cytotoxicity","volume":"21","author":"Ptaszy\u0144ska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0026","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.biopha.2018.09.097","article-title":"Cell penetrating peptides: a concise review with emphasis on biomedical applications","volume":"108","author":"Derakhshankhah","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0027","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.addr.2004.10.007","article-title":"Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides","volume":"57","author":"Gupta","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.106094_bib0028","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2014.08.014","article-title":"A survey on \u201cTrojan Horse\u201d peptides: opportunities, issues and controlled entry to \u201cTroy","volume":"194","author":"Shi","year":"2014","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0029","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0030","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/DDDT.S195481","article-title":"Transportan-derived cell-penetrating peptide delivers siRNA to inhibit replication of influenza virus in vivo","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2021.106094_bib0031","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00705-008-0125-7","article-title":"Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses","volume":"153","author":"Mino","year":"2008","journal-title":"Arch. Virol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/v11020109","article-title":"Cell-penetrating Mx1 enhances anti-viral resistance against mucosal influenza viral infection","volume":"11","author":"Jung","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0033","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2010.12.001","article-title":"Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production","volume":"89","author":"Pan","year":"2011","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0034","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3390\/cells9091989","article-title":"A broad-spectrum antiviral peptide blocks infection of viruses by binding to phosphatidylserine in the viral envelope","volume":"9","author":"Luteijn","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145986","article-title":"A cell internalizing antibody targeting capsid protein (p24) inhibits the replication of HIV-1 in T cells lines and PBMCS: a proof of concept study","volume":"11","author":"Ali","year":"2016","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.ejps.2021.106094_bib0036","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1016\/j.vaccine.2010.03.070","article-title":"The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice","volume":"28","author":"Chen","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0037","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1080\/22221751.2020.1812436","article-title":"Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice","volume":"9","author":"Yin","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0038","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/104303404772679977","article-title":"Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity","volume":"15","author":"Kim","year":"2004","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0039","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.3109\/10717544.2015.1108375","article-title":"The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model","volume":"23","author":"Mehrlatifan","year":"2016","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.biopha.2008.07.086","article-title":"Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide","volume":"63","author":"Wei","year":"2009","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0041","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/aid.2010.0295","article-title":"Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons","volume":"27","author":"Borgmann","year":"2011","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0042","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrmicro.2017.170","article-title":"Rewiring cellular networks by members of the Flaviviridae family","volume":"16","author":"Neufeldt","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejps.2021.106094_bib0043","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1146\/annurev-biochem-060208-104626","article-title":"Virus entry by endocytosis","volume":"79","author":"Mercer","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejps.2021.106094_bib0044","doi-asserted-by":"crossref","unstructured":"S. Payne, Chapter 1 Introduction to Animal Viruses, in: S. Payne (Ed.), Viruses, Academic Press 2017, 1\u201311.","DOI":"10.1016\/B978-0-12-803109-4.00001-5"},{"key":"10.1016\/j.ejps.2021.106094_bib0045","first-page":"31","article-title":"Virus life cycle","author":"Ryu","year":"2017","journal-title":"Molecular Virology of Human Pathogenic Viruses"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0046","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrmicro817","article-title":"Virus entry: molecular mechanisms and biomedical applications","volume":"2","author":"Dimitrov","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0047","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro1615","article-title":"Virus trafficking\u2013learning from single-virus tracking","volume":"5","author":"Brandenburg","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0048","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2006.02.007","article-title":"Virus entry: open sesame","volume":"124","author":"Marsh","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2021.106094_bib0049","article-title":"Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents","volume":"759","author":"Jans","year":"2020","journal-title":"Sci. Total Environ."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.chom.2010.06.010","article-title":"Cytoplasmic viral replication complexes","volume":"8","author":"Den Boon","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejps.2021.106094_bib0051","series-title":"Virus replication","author":"Harper","year":"2012"},{"key":"10.1016\/j.ejps.2021.106094_bib0052","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fmicb.2015.00552","article-title":"Archaeal viruses at the cell envelope: entry and egress","volume":"6","author":"Quemin","year":"2015","journal-title":"Front. Microbiol."},{"issue":"5033","key":"10.1016\/j.ejps.2021.106094_bib0053","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.1658933","article-title":"Molecular basis of latency in pathogenic human viruses","volume":"254","author":"Garcia-Blanco","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejps.2021.106094_bib0054","series-title":"Fenner and White's Medical Virology","first-page":"77","article-title":"Chapter 7 - pathogenesis of virus infections","author":"Burrell","year":"2017"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/03079450120044515","article-title":"Detection and differentiation of Newcastle disease virus (avian paramyxovirus type 1)","volume":"30","author":"Aldous","year":"2001","journal-title":"Avian Pathol."},{"key":"10.1016\/j.ejps.2021.106094_bib0056","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3389\/fmicb.2019.02314","article-title":"Factors affecting the tissue damaging consequences of viral infections","volume":"10","author":"Sumbria","year":"2019","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0057","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0058","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkm307","article-title":"Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells","volume":"60","author":"Michaelis","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0059","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/clin.1997.4477","article-title":"Immunoglobulin-and hepatitis B surface antigen-specific circulating immune complexes in chronic hepatitis B virus infection","volume":"86","author":"Tsai","year":"1998","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"12","key":"10.1016\/j.ejps.2021.106094_bib0060","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/CVI.00316-10","article-title":"How innate immune mechanisms contribute to antibody-enhanced viral infections","volume":"17","author":"Ubol","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ejps.2021.106094_bib0003","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","article-title":"Antivirals for COVID-19: a critical review","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02918552","article-title":"Molecular mimicry as a mechanism for virus-induced autoimmunity","volume":"8","author":"Fujinami","year":"1989","journal-title":"Immunol. Res."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0062","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/v11080762","article-title":"Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms","volume":"11","author":"Smatti","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0063","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imr.12091","article-title":"Virus infection, antiviral immunity, and autoimmunity","volume":"255","author":"Getts","year":"2013","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0064","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrd3162","article-title":"Calming the cytokine storm","volume":"9","author":"Harrison","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2021.106094_bib0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0066","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/PL00000625","article-title":"Generalized immunosuppression: how viruses undermine the immune response","volume":"57","author":"Naniche","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0067","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jfma.2013.09.001","article-title":"Pathogenesis of virus-associated human cancers: epstein\u2013Barr virus and hepatitis B virus as two examples","volume":"113","author":"Chang","year":"2014","journal-title":"J. Formos. Med. Assoc."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0068","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.172472","article-title":"Screening for 15 pathogenic viruses in human cell lines registered at the JCRB cell bank: characterization of in vitro human cells by viral infection","volume":"5","author":"Shioda","year":"2018","journal-title":"R. Soc. Open Sci."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0069","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0070","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3390\/nano10091645","article-title":"Antiviral potential of nanoparticles\u2014can nanoparticles fight against coronaviruses?","volume":"10","author":"Gurunathan","year":"2020","journal-title":"Nanomaterials"},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0071","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/med.21664","article-title":"Medicinal chemistry strategies toward host targeting antiviral agents","volume":"40","author":"Ji","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0072","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2021.106094_bib0073","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jpba.2017.07.003","article-title":"Current antiviral drugs and their analysis in biological materials\u2013part ii: antivirals against hepatitis and HIV viruses","volume":"147","author":"Nov\u00e1kov\u00e1","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0074","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process","volume":"2","author":"Irwin","year":"2016","journal-title":"Virus Evol."},{"key":"10.1016\/j.ejps.2021.106094_bib0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pharmthera.2015.07.003","article-title":"Cell-penetrating peptides transport therapeutics into cells","volume":"154","author":"Ramsey","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2021.106094_bib0076","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1039\/D0BM01755H","article-title":"Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics","volume":"9","author":"Desale","year":"2021","journal-title":"Biomater. Sci."},{"issue":"21","key":"10.1016\/j.ejps.2021.106094_bib0077","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/sj.gt.3301819","article-title":"Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity","volume":"9","author":"Leifert","year":"2002","journal-title":"Gene Ther."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2021.106094_bib0078","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jns.2015.08.1549","article-title":"Effects of low doses of Tat-PIM2 protein against hippocampal neuronal cell survival","volume":"358","author":"Woo","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0079","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","article-title":"Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein","volume":"55","author":"Green","year":"1988","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0080","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2021.106094_bib0081","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.peptides.2014.04.015","article-title":"Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules","volume":"57","author":"Farkhani","year":"2014","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0082","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bmcl.2016.11.083","article-title":"Intelligent substance delivery into cells using cell-penetrating peptides","volume":"27","author":"Tashima","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2021.106094_bib0083","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2020.00697","article-title":"Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejps.2021.106094_bib0084","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.tibs.2015.10.004","article-title":"Mechanism matters: a taxonomy of cell penetrating peptides","volume":"40","author":"Kauffman","year":"2015","journal-title":"Trends Biochem. Sci."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0085","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3390\/molecules22111929","article-title":"Cell-penetrating peptides: design strategies beyond primary structure and amphipathicity","volume":"22","author":"Kalafatovic","year":"2017","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0086","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3762\/bjnano.11.10","article-title":"Internalization mechanisms of cell-penetrating peptides","volume":"11","author":"Ruseska","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0087","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.febslet.2009.11.046","article-title":"Arginine-rich cell-penetrating peptides","volume":"584","author":"Schmidt","year":"2010","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0088","doi-asserted-by":"crossref","first-page":"e3071","DOI":"10.1002\/btpr.3071","article-title":"Introducing a delivery system for melanogenesis inhibition in melanoma B16F10 cells mediated by the conjugation of tyrosine ammonia-lyase and a TAT-penetrating peptide","volume":"37","author":"Behzadipour","year":"2021","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0089","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1570164616666190701120351","article-title":"Cell penetrating peptide: sequence-based computational prediction for intercellular delivery of arginine deiminase","volume":"17","author":"Zarei","year":"2020","journal-title":"Curr. Proteom."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00109-010-0693-3","article-title":"Successful TAT-mediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency","volume":"89","author":"Rapoport","year":"2011","journal-title":"J. Mol. Med."},{"issue":"22","key":"10.1016\/j.ejps.2021.106094_bib0091","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1007\/s00018-008-8222-z","article-title":"Cell penetrating peptide inhibitors of nuclear factor-kappa B","volume":"65","author":"Orange","year":"2008","journal-title":"Cell. Mol. Life. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0092","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.bbrc.2011.12.084","article-title":"Anti-inflammatory effects of Tat-Annexin protein on ovalbumin-induced airway inflammation in a mouse model of asthma","volume":"417","author":"Lee","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0093","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbcan.2009.09.004","article-title":"Cell-penetrating peptides: application in vaccine delivery","volume":"1805","author":"Brooks","year":"2010","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ejps.2021.106094_bib0094","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejps.2021.106094_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2020.110119","article-title":"Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: a review","volume":"191","author":"Mukherjee","year":"2020","journal-title":"Environ. Res."},{"key":"10.1016\/j.ejps.2021.106094_bib0096","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.antiviral.2016.01.008","article-title":"PTD-fused p53 as a potential antiviral agent directly suppresses HBV transcription and expression","volume":"127","author":"Chu","year":"2016","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0097","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-017-0019-3","article-title":"Antibody therapies for the prevention and treatment of viral infections","volume":"2","author":"Salazar","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ejps.2021.106094_bib0098","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.coph.2020.09.011","article-title":"RNAi therapeutics: an antiviral strategy for human infections","volume":"54","author":"Kelleher","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0099","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/biom2020187","article-title":"Cell penetrating peptides in the delivery of biopharmaceuticals","volume":"2","author":"Munyendo","year":"2012","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0100","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1073\/pnas.1917748117","article-title":"Cell-penetrating peptide inhibits retromer-mediated human papillomavirus trafficking during virus entry","volume":"117","author":"Zhang","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170443","article-title":"Antiviral peptides against enterovirus A71 causing hand, foot and mouth disease","volume":"136","author":"Lalani","year":"2021","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002038","article-title":"Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA","volume":"7","author":"Lalonde","year":"2011","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0102","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ijmm.2012.1210","article-title":"Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro","volume":"31","author":"Xun","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejps.2021.106094_bib0103","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1038\/mtna.2016.11","article-title":"A Tat-conjugated peptide nucleic acid Tat-PNA-DR inhibits hepatitis B virus replication and in vivo by targeting LTR direct repeats of HBV RNA","volume":"5","author":"Zeng","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"21","key":"10.1016\/j.ejps.2021.106094_bib0104","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1093\/nar\/gki991","article-title":"Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells","volume":"33","author":"Turner","year":"2005","journal-title":"Nucleic. Acids Res."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.antiviral.2009.07.020","article-title":"Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27","volume":"84","author":"Moerdyk-Schauwecker","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejps.2021.106094_bib0106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jconrel.2017.06.026","article-title":"Pathogen-mimicking vaccine delivery system designed with a bioactive polymer (inulin acetate) for robust humoral and cellular immune responses","volume":"261","author":"Kumar","year":"2017","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0107","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","article-title":"Nanotechnology in vaccine delivery","volume":"60","author":"Peek","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1020198908574","article-title":"Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs","volume":"22","author":"Bungener","year":"2002","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.ejps.2021.106094_bib0109","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.biomaterials.2012.12.031","article-title":"A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy","volume":"34","author":"Yuba","year":"2013","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0110","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/cncr.22978","article-title":"Breast cancer vaccines: promise for the future or pipe dream?","volume":"110","author":"Mittendorf","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-77024-y","article-title":"Human leukocyte antigen class II quantification by targeted mass spectrometry in dendritic-like cell lines and monocyte-derived dendritic cells","volume":"11","author":"Casasola-LaMacchia","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0112","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4110\/in.2016.16.1.33","article-title":"Use of cell-penetrating peptides in dendritic cell-based vaccination","volume":"16","author":"Lim","year":"2016","journal-title":"Immune. Netw."},{"issue":"25","key":"10.1016\/j.ejps.2021.106094_bib0113","doi-asserted-by":"crossref","first-page":"eaaz4462","DOI":"10.1126\/sciadv.aaz4462","article-title":"The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency","volume":"6","author":"Hong","year":"2020","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0114","first-page":"465","article-title":"Cell-Penetrating Peptides in Vaccine Delivery: Facts, Challenges and Perspectives","volume":"8","author":"Skwarczynski","year":"2019","journal-title":"Future Science"},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2174\/1567201816666190123120915","article-title":"Cell-penetrating peptides: efficient vectors for vaccine delivery","volume":"16","author":"Yang","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-40594-7","article-title":"Induction of tumor-specific CTL responses using the C-terminal fragment of viral protein R as cell penetrating peptide","volume":"9","author":"Gross","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0117","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s10529-021-03166-2","article-title":"A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 Linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses","volume":"43","author":"Mousavi","year":"2021","journal-title":"Biotechnol. Lett."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0118","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.vaccine.2011.12.029","article-title":"A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57\/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice","volume":"30","author":"Tang","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0119","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.vaccine.2010.11.083","article-title":"A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice","volume":"29","author":"Granadillo","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ejps.2021.106094_bib0120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.meegid.2017.08.002","article-title":"A novel HPV prophylactic peptide vaccine, designed by immunoinformatics and structural vaccinology approaches","volume":"54","author":"Negahdaripour","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.ejps.2021.106094_bib0121","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.intimp.2018.07.006","article-title":"Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines","volume":"62","author":"Shahbazi","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0122","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3892\/br.2016.647","article-title":"Protein transduction domain can enhance the humoral immunity and cross\u2011protection of HPV16L2 peptide vaccines","volume":"4","author":"Li","year":"2016","journal-title":"Biomed. Rep."},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0123","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","article-title":"The evolution and clinical impact of hepatitis B virus genome diversity","volume":"17","author":"Revill","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2567.2007.02543.x","article-title":"Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2\u2022 1\/Kb transgenic mice","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2893.2006.00734.x","article-title":"HBV genes induce cytotoxic T-lymphocyte response upon adeno-associated virus (AAV) vector delivery into dendritic cells","volume":"13","author":"You","year":"2006","journal-title":"J. Viral Hepat."},{"issue":"12","key":"10.1016\/j.ejps.2021.106094_bib0126","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1745-7270.2008.00487.x","article-title":"Enhancement of cytotoxic T lymphocyte activity by dendritic cells loaded with Tat-protein transduction domain-fused hepatitis B virus core antigen","volume":"40","author":"Chen","year":"2008","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0127","first-page":"107","article-title":"in vitro Delivery of HIV-1 Nef Antigen by Histidine-rich nona-arginine and Latarcin 1 peptide","volume":"7","author":"Namazi","year":"2019","journal-title":"J.Med. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejps.2021.106094_bib0129","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10529-020-02918-w","article-title":"B1 protein: a novel cell penetrating protein for in vitro and in vivo delivery of HIV-1 multi-epitope DNA constructs","volume":"42","author":"Kardani","year":"2020","journal-title":"Biotechnol. Lett."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2021.106094_bib0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molimm.2012.07.011","article-title":"Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections","volume":"53","author":"Mohit","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejps.2021.106094_bib0131","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.imlet.2019.06.011","article-title":"Simultaneous use of natural adjuvants and cell penetrating peptides improves HCV NS3 antigen-specific immune responses","volume":"212","author":"Alizadeh","year":"2019","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0132","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1248\/cpb.c17-00834","article-title":"Effects of the chemical structures of oligoarginines conjugated to biocompatible polymers as a mucosal adjuvant on antibody induction in nasal cavities","volume":"66","author":"Mohri","year":"2018","journal-title":"Chem. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0133","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2006.04.015","article-title":"A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus","volume":"354","author":"Saha","year":"2006","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0134","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11373-005-9012-3","article-title":"Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies","volume":"12","author":"Peng","year":"2005","journal-title":"J. Biomed. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0135","first-page":"725","article-title":"Immunogenicity of DNA vaccine expressing GP5 of porcine reproductive and respiratory syndrome virus fused with VP22 of bovine herpesvirus 1","volume":"21","author":"Zhao","year":"2005","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"issue":"15","key":"10.1016\/j.ejps.2021.106094_bib0136","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1089\/104303401753153938","article-title":"Enhancing T cell activation and antiviral protection by introducing the HIV-1 protein transduction domain into a DNA vaccine","volume":"12","author":"Leifert","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejps.2021.106094_bib0137","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.imlet.2017.06.003","article-title":"Combination of cell penetrating peptides and heterologous DNA prime\/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB\/c mouse model","volume":"188","author":"Kadkhodayan","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejps.2021.106094_bib0138","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0139","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/vaccines9020148","article-title":"mRNA vaccines against flaviviruses","volume":"9","author":"Wollner","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ejps.2021.106094_bib0140","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. immunol."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0141","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.vaccine.2020.12.084","article-title":"Anaphylactic reactions to novel mRNA SARS-CoV-2\/COVID-19 vaccines","volume":"39","author":"Kelso","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0142","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/vaccines9020076","article-title":"Delivery of mRNA vaccine against SARS-CoV-2 using a polyglucin: spermidine conjugate","volume":"9","author":"Karpenko","year":"2021","journal-title":"Vaccines"},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0143","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/15058","article-title":"Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat. Biotechnol."},{"issue":"13","key":"10.1016\/j.ejps.2021.106094_bib0144","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201601412","article-title":"Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide","volume":"6","author":"Udhayakumar","year":"2017","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.vaccine.2012.11.011","article-title":"TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses","volume":"31","author":"Zhao","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0146","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.xphs.2016.03.026","article-title":"Cell-penetrating peptide penetratin as a potential tool for developing effective nasal vaccination systems","volume":"105","author":"Muto","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0147","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biomaterials.2017.03.007","article-title":"Engineering intravaginal vaccines to overcome mucosal and epithelial barriers","volume":"128","author":"Ji","year":"2017","journal-title":"Biomaterials"},{"issue":"15\u201316","key":"10.1016\/j.ejps.2021.106094_bib0148","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.vaccine.2003.10.028","article-title":"Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes","volume":"22","author":"Schutze-Redelmeier","year":"2004","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0149","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2014.09.017","article-title":"Therapeutic applications of the cell-penetrating HIV-1 Tat peptide","volume":"20","author":"Rizzuti","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0150","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1021\/acs.bioconjchem.1c00123","article-title":"Penetrating the blood-brain barrier with new peptide\u2013porphyrin conjugates having anti-HIV activity","volume":"32","author":"Mendon\u00e7a","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"12","key":"10.1016\/j.ejps.2021.106094_bib0151","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2019.1652592","article-title":"Selected application of peptide molecules as pharmaceutical agents and in cosmeceuticals","volume":"19","author":"Negahdaripour","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejps.2021.106094_bib0152","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.peptides.2016.11.011","article-title":"In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides","volume":"87","author":"Bolhassani","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.ejps.2021.106094_bib0153","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.compbiomed.2019.02.011","article-title":"AntiVPP 1.0: a portable tool for prediction of antiviral peptides","volume":"107","author":"Lissabet","year":"2019","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.ejps.2021.106094_bib0154","first-page":"1","article-title":"Antiviral peptides: identification and validation","author":"Agarwal","year":"2020","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"7","key":"10.1016\/j.ejps.2021.106094_bib0156","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1080\/07391102.2017.1333459","article-title":"Virucidal activity of cell-penetrating peptides of viral origin","volume":"36","author":"Abd El-Baky","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejps.2021.106094_bib0157","doi-asserted-by":"crossref","first-page":"601555","DOI":"10.3389\/fmicb.2020.601555","article-title":"A novel, broad-acting peptide inhibitor of double-stranded DNA virus gene expression and replication","volume":"11","author":"Ruzsics","year":"2020","journal-title":"Front. Microbiol."},{"issue":"39","key":"10.1016\/j.ejps.2021.106094_bib0158","doi-asserted-by":"crossref","first-page":"36018","DOI":"10.1074\/jbc.M204849200","article-title":"Peptides containing membrane-transiting motifs inhibit virus entry","volume":"277","author":"Bultmann","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0159","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1016\/S1074-5521(00)00106-X","article-title":"Antagonists of protein\u2013protein interactions","volume":"7","author":"Cochran","year":"2000","journal-title":"Chem. Biol."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0160","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/AAC.01009-06","article-title":"Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain","volume":"51","author":"Bultmann","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0162","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/AAC.01424-07","article-title":"Inhibition of herpes simplex virus type 1 infection by cationic \u03b2-peptides","volume":"52","author":"Akkarawongsa","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0163","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmb.2008.02.066","article-title":"A cell-penetrating helical peptide as a potential HIV-1 inhibitor","volume":"378","author":"Zhang","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"24","key":"10.1016\/j.ejps.2021.106094_bib0164","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1128\/JVI.01678-06","article-title":"Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells","volume":"80","author":"Jones","year":"2006","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0165","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1128\/JVI.75.6.2634-2645.2001","article-title":"Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1","volume":"75","author":"Bultmann","year":"2001","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0166","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/biom8030055","article-title":"Developments in cell-penetrating peptides as antiviral agents and as vehicles for delivery of peptide nucleic acid targeting hepadnaviral replication pathway","volume":"8","author":"Ndeboko","year":"2018","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0167","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/4710","article-title":"Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein","volume":"5","author":"Vocero-Akbani","year":"1999","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0168","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.antiviral.2013.05.009","article-title":"in vitro inhibition of vesicular stomatitis virus replication by purified porcine Mx1 protein fused to HIV-1 Tat protein transduction domain (PTD)","volume":"99","author":"Zhang","year":"2013","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.antiviral.2007.11.006","article-title":"Creation of a bi-directional protein transduction system for suppression of HIV-1 expression by p27SJ","volume":"79","author":"Darbinian","year":"2008","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-55091-0","article-title":"Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions","volume":"9","author":"Gaston","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0172","doi-asserted-by":"crossref","first-page":"8724549","DOI":"10.1155\/2018\/8724549","article-title":"Antibody-mediated therapy against HIV\/AIDS: where are we standing now?","volume":"2018","author":"Awi","year":"2018","journal-title":"J. Pathog."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0173","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2217\/nnm.13.139","article-title":"Intracellular neutralization of a virus using a cell-penetrating molecular transporter","volume":"9","author":"Sapparapu","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2021.106094_bib0174","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","article-title":"Single-domain antibodies as therapeutics against human viral diseases","volume":"8","author":"Wu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2021.106094_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118919","article-title":"DNA vaccines against COVID-19: perspectives and challenges","volume":"267","author":"Silveira","year":"2021","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0175","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1021\/acs.bioconjchem.9b00025","article-title":"Antibody delivery for intracellular targets: emergent therapeutic potential","volume":"30","author":"Singh","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0176","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.intimp.2015.01.028","article-title":"Transbody against hepatitis B virus core protein inhibits hepatitis B virus replication in vitro","volume":"25","author":"Wang","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0177","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7150\/thno.20047","article-title":"A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"issue":"14","key":"10.1016\/j.ejps.2021.106094_bib0178","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/bph.13811","article-title":"Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: evidence from a duck model of hepatitis B virus","volume":"174","author":"Li","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0179","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bbrc.2018.11.170","article-title":"Design and assessment of an active anti-epidermal growth factor receptor (EGFR) single chain variable fragment (ScFv) with improved solubility","volume":"508","author":"Nautiyal","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0180","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.biotechadv.2009.04.004","article-title":"Applications of single-chain variable fragment antibodies in therapeutics and diagnostics","volume":"27","author":"Weisser","year":"2009","journal-title":"Biotechnol. Adv."},{"issue":"16","key":"10.1016\/j.ejps.2021.106094_bib0181","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.vaccine.2006.01.055","article-title":"Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies","volume":"24","author":"Theisen","year":"2006","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.ejps.2021.106094_bib0182","doi-asserted-by":"crossref","first-page":"20222","DOI":"10.1074\/jbc.M114.581090","article-title":"A cell-penetrating antibody fragment against HIV-1 Rev has high antiviral activity: characterization of the paratope","volume":"289","author":"Zhuang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2021.106094_bib0183","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fimmu.2016.00318","article-title":"Human transbodies to HCV NS3\/4A protease inhibit viral replication and restore host innate immunity","volume":"7","author":"Jittavisutthikul","year":"2016","journal-title":"Front. immunol."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-14886-9","article-title":"Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virus","volume":"7","author":"Glab-Ampai","year":"2017","journal-title":"Sci. Rep."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2021.106094_bib0185","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jviromet.2013.08.032","article-title":"Humanized-VH\/VHH that inhibit HCV replication by interfering with the virus helicase activity","volume":"194","author":"Phalaphol","year":"2013","journal-title":"J. Virol. Methods"},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0186","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.bbrc.2016.05.109","article-title":"Inhibition of HCV replication by humanized-single domain transbodies to NS4B","volume":"476","author":"Glab-Ampai","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0187","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3390\/v7042030","article-title":"Humanized-VHH transbodies that inhibit HCV protease and replication","volume":"7","author":"Jittavisutthikul","year":"2015","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.ejps.2021.106094_bib0188","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1021\/bc900251u","article-title":"A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus","volume":"21","author":"Poungpair","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0189","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/v7010154","article-title":"Cell penetrable human scFv specific to middle domain of matrix protein-1 protects mice from lethal influenza","volume":"7","author":"Dong-Din-On","year":"2015","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbrc.2016.09.052","article-title":"Human transbodies to VP40 inhibit cellular egress of Ebola virus-like particles","volume":"479","author":"Teimoori","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41426-018-0031-3","article-title":"Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism","volume":"7","author":"Seesuay","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ejps.2021.106094_bib0192","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104921","article-title":"Interference of dengue replication by blocking the access of 3\u2032 SL RNA to the viral RNA-dependent RNA polymerase","volume":"182","author":"Tunghirun","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejps.2021.106094_bib0193","first-page":"11","article-title":"Human antibodies to VP4 inhibit replication of enteroviruses across subgenotypes and serotypes, and enhance host innate immunity","author":"Phanthong","year":"2020","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0194","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4161\/mabs.29978","article-title":"Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase","volume":"6","author":"Thueng-in","year":"2014","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0928-0987(00)00209-8","article-title":"Development of gene drug delivery systems based on pharmacokinetic studies","volume":"13","author":"Takakura","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0161","doi-asserted-by":"crossref","first-page":"349427","DOI":"10.1155\/2012\/349427","article-title":"Infection by CXCR4-tropic human immunodeficiency virus type 1 is inhibited by the cationic cell-penetrating peptide derived from HIV-1 tat","volume":"2012","author":"Keogan","year":"2012","journal-title":"Int. J. Pept."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2021.106094_bib0196","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2018.01.007","article-title":"An efficient PEGylated gene delivery system with improved targeting: synergism between octaarginine and a fusogenic peptide","volume":"538","author":"Khalil","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.106094_bib0197","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0198","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0199","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0200","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.gt.3302479","article-title":"siRNA targeting the leader sequence of SARS-CoV inhibits virus replication","volume":"12","author":"Li","year":"2005","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0201","doi-asserted-by":"crossref","first-page":"e1976","DOI":"10.1002\/rmv.1976","article-title":"A review on current status of antiviral siRNA","volume":"28","author":"Qureshi","year":"2018","journal-title":"Rev. Med. Virol."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0202","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/mt.2011.284","article-title":"Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery","volume":"20","author":"Margus","year":"2012","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0203","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/molecules26040956","article-title":"Oligonucleotide-based approaches to inhibit dengue virus replication","volume":"26","author":"Panda","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0204","first-page":"1","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s41061-017-0127-6","article-title":"Polymers in the delivery of siRNA for the treatment of virus infections","volume":"375","author":"Reynolds","year":"2017","journal-title":"Top. Curr. Chem."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0206","article-title":"Insights into RNA interference as antiviral defense","volume":"7","author":"Purushottam","year":"2016","journal-title":"J. AIDS Clin. Res."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0207","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s13337-018-00508-z","article-title":"siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection","volume":"30","author":"Manda","year":"2019","journal-title":"Virusdisease"},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0208","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1582-4934.2012.01572.x","article-title":"Cellular micro RNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells","volume":"16","author":"Ma","year":"2012","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0209","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JVI.02608-15","article-title":"Human microRNA miR-532-5p exhibits antiviral activity against West Nile virus via suppression of host genes SESTD1 and TAB3 required for virus replication","volume":"90","author":"Slonchak","year":"2016","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejpb.2013.03.021","article-title":"Is there a future for cell-penetrating peptides in oligonucleotide delivery?","volume":"85","author":"Lee","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0211","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.biomaterials.2009.11.001","article-title":"The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine","volume":"31","author":"Choi","year":"2010","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/1061186X.2016.1245311","article-title":"Chimeric peptide-mediated siRNA transduction to inhibit HIV-1 infection","volume":"25","author":"Bivalkar-Mehla","year":"2017","journal-title":"J. Drug Target."},{"issue":"24","key":"10.1016\/j.ejps.2021.106094_bib0213","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1021\/acs.biochem.0c00141","article-title":"Hexokinase II-derived cell-penetrating peptide mediates delivery of MicroRNA mimic for cancer-selective cytotoxicity","volume":"59","author":"Palanikumar","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2021.106094_bib0214","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120316","article-title":"NickFect type of cell-penetrating peptides present enhanced efficiency for microRNA-146a delivery into dendritic cells and during skin inflammation","volume":"262","author":"Carreras-Badosa","year":"2020","journal-title":"Biomaterials"},{"issue":"17","key":"10.1016\/j.ejps.2021.106094_bib0215","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/j.biomaterials.2013.02.039","article-title":"Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation","volume":"34","author":"Suh","year":"2013","journal-title":"Biomaterials"},{"issue":"4\u20135","key":"10.1016\/j.ejps.2021.106094_bib0216","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.addr.2007.09.002","article-title":"Cell penetrating peptide conjugates of steric block oligonucleotides","volume":"60","author":"Lebleu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0217","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.cr.7290209","article-title":"Peptide nucleic acid (PNA) binding-mediated gene regulation","volume":"14","author":"Gan","year":"2004","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0218","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2007.01.016","article-title":"Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome","volume":"363","author":"Tripathi","year":"2007","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.ejps.2021.106094_bib0219","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1111\/j.1365-2893.2010.01416.x","article-title":"Interference of hepatitis C virus replication in cell culture by antisense peptide nucleic acids targeting the X-RNA","volume":"18","author":"Ahn","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2011.04.009","article-title":"Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication","volume":"91","author":"Ahn","year":"2011","journal-title":"Antiviral Res."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2021.106094_bib0221","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virusres.2008.10.018","article-title":"Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers","volume":"140","author":"Sleeman","year":"2009","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0222","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2009.02.187","article-title":"Inhibition of Japanese encephalitis virus replication by peptide nucleic acids targeting cis-acting elements on the plus-and minus-strands of viral RNA","volume":"82","author":"Yoo","year":"2009","journal-title":"Antiviral Res."},{"issue":"23","key":"10.1016\/j.ejps.2021.106094_bib0223","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1128\/JVI.00900-06","article-title":"Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site","volume":"80","author":"Yuan","year":"2006","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0224","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jac\/dkaa460","article-title":"Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers","volume":"76","author":"Rosenke","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0225","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.00644-06","article-title":"Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers","volume":"50","author":"Ge","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0226","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1128\/JVI.79.8.5116-5128.2005","article-title":"Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers","volume":"79","author":"Kinney","year":"2005","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0227","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1128\/JVI.79.8.4599-4609.2005","article-title":"Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication","volume":"79","author":"Deas","year":"2005","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0228","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1128\/AAC.50.3.984-993.2006","article-title":"VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice","volume":"50","author":"Enterlein","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0229","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.01294-10","article-title":"Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2","volume":"85","author":"B\u00f6ttcher-Friebertsh\u00e4user","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.ejps.2021.106094_bib0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cbpa.2019.06.006","article-title":"Peptide nucleic acid (PNA) and its applications in chemical biology, diagnostics, and therapeutics","volume":"52","author":"Saarbach","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejps.2021.106094_bib0231","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ab.2018.07.006","article-title":"Detection of unique Ebola virus oligonucleotides using fluorescently-labeled phosphorodiamidate morpholino oligonucleotide probe pairs","volume":"557","author":"Xiong","year":"2018","journal-title":"Anal. Biochem."},{"issue":"13","key":"10.1016\/j.ejps.2021.106094_bib0232","doi-asserted-by":"crossref","first-page":"11411","DOI":"10.1074\/jbc.M211891200","article-title":"Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells","volume":"278","author":"Rudolph","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.ejps.2021.106094_bib0233","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201464","article-title":"mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446","volume":"13","author":"Bell","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0234","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/21691401.2016.1200059","article-title":"Enhancing antitumor activity of silver nanoparticles by modification with cell-penetrating peptides","volume":"45","author":"Mussa Farkhani","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","article-title":"Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections","volume":"15","author":"Lembo","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0236","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP1684","article-title":"Nanoparticulate delivery systems for antiviral drugs","volume":"21","author":"Lembo","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0237","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s13346-020-00818-0","article-title":"Nanotechnology-based antiviral therapeutics","volume":"11","author":"Chakravarty","year":"2020","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2021.106094_bib0238","first-page":"328","article-title":"Antiretroviral therapy through barriers: a prominent role for nanotechnology in HIV-1 eradication from sanctuaries","volume":"4","author":"Corsi","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0239","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/pharmaceutics12020171","article-title":"Nanomaterials designed for antiviral drug delivery transport across biological barriers","volume":"12","author":"Cojocaru","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106094_bib0240","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8043983","article-title":"Liposomal systems as nanocarriers for the antiviral agent ivermectin","volume":"2016","author":"Croci","year":"2016","journal-title":"Int. J. Biomater."},{"key":"10.1016\/j.ejps.2021.106094_bib0241","doi-asserted-by":"crossref","DOI":"10.1016\/j.nanoso.2020.100620","article-title":"Nano-based antiviral coatings to combat viral infections","volume":"24","author":"Basak","year":"2020","journal-title":"Nano Struct. Nano Objects"},{"key":"10.1016\/j.ejps.2021.106094_bib0242","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101019","article-title":"Insights from nanotechnology in COVID-19 treatment","volume":"36","author":"Tang","year":"2021","journal-title":"Nano Today"},{"issue":"33","key":"10.1016\/j.ejps.2021.106094_bib0243","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1016\/j.biomaterials.2008.08.004","article-title":"TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs","volume":"29","author":"Rao","year":"2008","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0244","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.biomaterials.2011.12.015","article-title":"Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown","volume":"33","author":"Ryoo","year":"2012","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0245","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0246","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/vim.2019.0032","article-title":"Role of the innate cytokine storm induced by the influenza A virus","volume":"32","author":"Gu","year":"2019","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ejps.2021.106094_bib0247","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114055","article-title":"Mn-TAT PTD-Ngb ameliorates inflammation through the elimination of damaged mitochondria and the activation of Nrf2-antioxidant signaling pathway","volume":"178","author":"Zhang","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2021.106094_bib0248","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.intimp.2016.08.026","article-title":"Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways","volume":"40","author":"Roy","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.ejps.2021.106094_bib0249","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejps.2021.106094_bib0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exer.2018.07.020","article-title":"A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis","volume":"177","author":"Ahmed","year":"2018","journal-title":"Exp. Eye Res."},{"issue":"5","key":"10.1016\/j.ejps.2021.106094_bib0251","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/ml300041g","article-title":"Anti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2\/Keap1 interaction","volume":"3","author":"Steel","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0252","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56455-2","article-title":"Effective lung-targeted RNAi in mice with peptide-based delivery of nucleic acid","volume":"9","author":"Kurrikoff","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0253","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/pharmaceutics11090478","article-title":"Therapeutic effects in a transient middle cerebral artery occlusion rat model by nose-to-brain delivery of anti-TNF-alpha siRNA with cell-penetrating peptide-modified polymer micelles","volume":"11","author":"Kanazawa","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2021.106094_bib0254","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2017.06.012","article-title":"A novel IL-1RA-PEP fusion protein with enhanced brain penetration ameliorates cerebral ischemia-reperfusion injury by inhibition of oxidative stress and neuroinflammation","volume":"297","author":"Zhang","year":"2017","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0255","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.foodchem.2012.04.024","article-title":"Regulation of virus-induced inflammatory response by \u03b2-carotene in RAW264. 7 cells","volume":"134","author":"Lin","year":"2012","journal-title":"Food Chem."},{"issue":"25","key":"10.1016\/j.ejps.2021.106094_bib0256","doi-asserted-by":"crossref","first-page":"24127","DOI":"10.1074\/jbc.M413726200","article-title":"The I\u03baB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells","volume":"280","author":"Bernasconi","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0257","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/vim.2010.0016","article-title":"PPAR-\u03b3 activation as an anti-inflammatory therapy for respiratory virus infections","volume":"23","author":"Bassaganya-Riera","year":"2010","journal-title":"Viral Immunol."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0258","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/viro.1998.9562","article-title":"Rubella virus-induced apoptosis varies among cell lines and is modulated by Bcl-XL and caspase inhibitors","volume":"255","author":"Duncan","year":"1999","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.ejps.2021.106094_bib0259","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/10556","article-title":"Inhibition of virus-induced neuronal apoptosis by Bax","volume":"5","author":"Lewis","year":"1999","journal-title":"Nat. Med."},{"issue":"4\u20135","key":"10.1016\/j.ejps.2021.106094_bib0260","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.addr.2007.09.011","article-title":"PTD-mediated delivery of anti-cell death proteins\/peptides and therapeutic enzymes","volume":"60","author":"Asoh","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0261","doi-asserted-by":"crossref","first-page":"e35187","DOI":"10.1371\/journal.pone.0035187","article-title":"TumorHoPe: a database of tumor homing peptides","volume":"7","author":"Kapoor","year":"2012","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.ejps.2021.106094_bib0262","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1073\/pnas.82.23.8057","article-title":"The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets","volume":"82","author":"Plow","year":"1985","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0263","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/cancers11101571","article-title":"Folate receptor-targeted albumin nanoparticles based on microfluidic technology to deliver cabazitaxel","volume":"11","author":"Meng","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejps.2021.106094_bib0264","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136649","article-title":"A novel isoquinoline derivative anticancer agent and its targeted delivery to tumor cells using transferrin-conjugated liposomes","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2021.106094_bib0265","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2147\/IJN.S126865","article-title":"Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles","volume":"12","author":"Chu","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejps.2021.106094_bib0266","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2014.12.002","article-title":"15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting","volume":"205","author":"Ye","year":"2015","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ejps.2021.106094_bib0267","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.addr.2012.11.007","article-title":"Curb challenges of the \u201cTrojan Horse\u201d approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery","volume":"65","author":"Huang","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.106094_bib0268","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2020.00697","article-title":"Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"32","key":"10.1016\/j.ejps.2021.106094_bib0269","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.1016\/j.biomaterials.2013.07.014","article-title":"A pH-responsive \u03b1-helical cell penetrating peptide-mediated liposomal delivery system","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0270","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/bc060080h","article-title":"SMART\u201d drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers","volume":"17","author":"Sawant","year":"2006","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0271","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.12.002","article-title":"Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity","volume":"160","author":"Koren","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2021.106094_bib0272","first-page":"6199","article-title":"An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery","volume":"10","author":"Ding","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0273","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/nn300524f","article-title":"Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting","volume":"6","author":"Zhu","year":"2012","journal-title":"ACS Nano"},{"issue":"5\u20136","key":"10.1016\/j.ejps.2021.106094_bib0274","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1039\/b904878b","article-title":"Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides","volume":"1","author":"Aguilera","year":"2009","journal-title":"Integr. Biol."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0275","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/ph5111177","article-title":"Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges","volume":"5","author":"Erazo-Oliveras","year":"2012","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0276","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2006.02.002","article-title":"Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes","volume":"112","author":"Boeckle","year":"2006","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0277","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2010.08.023","article-title":"Reprint of: nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation","volume":"149","author":"Akita","year":"2011","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0278","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.peptides.2012.07.019","article-title":"Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence","volume":"37","author":"Liou","year":"2012","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.ejps.2021.106094_bib0279","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.addr.2009.04.005","article-title":"Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape","volume":"61","author":"Endoh","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0280","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1208\/aapsj0901003","article-title":"Peptide-guided gene delivery","volume":"9","author":"Martin","year":"2007","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.ejps.2021.106094_bib0281","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1208\/s12248-008-9071-2","article-title":"Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment","volume":"11","author":"El-Sayed","year":"2009","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0282","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4155\/tde.15.2","article-title":"Cationic cell-penetrating peptides as vehicles for siRNA delivery","volume":"6","author":"Beloor","year":"2015","journal-title":"Ther. Deliv."},{"issue":"15","key":"10.1016\/j.ejps.2021.106094_bib0283","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.biomaterials.2008.01.031","article-title":"An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection","volume":"29","author":"Lo","year":"2008","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0284","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/mt.2009.192","article-title":"Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis","volume":"17","author":"Nakase","year":"2009","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2021.106094_bib0285","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/bc900577e","article-title":"S413-PV cell-penetrating peptide forms nanoparticle-like structures to gain entry into cells","volume":"21","author":"Padari","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0286","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1096\/fj.05-5523com","article-title":"Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells","volume":"20","author":"T\u00fcnnemann","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2021.106094_bib0287","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2013.11.020","article-title":"Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery","volume":"174","author":"Wang","year":"2014","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0288","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2021.106094_bib0289","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2014.06.022","article-title":"In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin","volume":"189","author":"Nielsen","year":"2014","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ejps.2021.106094_bib0290","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jconrel.2012.07.022","article-title":"Direct cytosolic delivery of cargoes in vivo by a chimera consisting of d-and l-arginine residues","volume":"162","author":"Ma","year":"2012","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0291","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1042\/BJ20040238","article-title":"Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat (47\u201357) and penetratin (43\u201358)","volume":"382","author":"Tr\u00e9hin","year":"2004","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.ejps.2021.106094_bib0292","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbamem.2005.10.006","article-title":"Developing novel hCT derived cell-penetrating peptides with improved metabolic stability","volume":"1758","author":"Rennert","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0293","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.bbamem.2012.05.003","article-title":"Membrane adsorption and binding, cellular uptake and cytotoxicity of cell-penetrating peptidomimetics with \u03b1-peptide\/\u03b2-peptoid backbone: effects of hydrogen bonding and \u03b1-chirality in the \u03b2-peptoid residues","volume":"1818","author":"Jing","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.ejps.2021.106094_bib0294","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1021\/la204033u","article-title":"Interaction of peptidomimetics with bilayer membranes: biophysical characterization and cellular uptake","volume":"28","author":"Jing","year":"2012","journal-title":"Langmuir"},{"issue":"18","key":"10.1016\/j.ejps.2021.106094_bib0295","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/acs.biochem.6b00226","article-title":"Discovery and mechanism of highly efficient cyclic cell-penetrating peptides","volume":"55","author":"Qian","year":"2016","journal-title":"Biochemistry"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872100395X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872100395X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:00:43Z","timestamp":1760529643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872100395X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":295,"alternative-id":["S092809872100395X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106094","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential of cell-penetrating peptides (CPPs) in delivery of antiviral therapeutics and vaccines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.106094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106094"}}